Recent studies have highlighted the importance of MSA status, especially anti-MDA5 and anti-ARS antibodies, for the evaluation of clinical phenotypes and for the choice of initial treatment in PM-/DM-/CADM-ILD. The gene discussed is IFIH1; the disease is dermatomyositis.